UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Main results already published
Unique ID issued by UMIN UMIN000002152
Receipt No. R000002632
Scientific Title A phase 1 study of combination therapy with gemcitabine and candesartan in patients with pancreatic cancer
Date of disclosure of the study information 2009/07/01
Last modified on 2015/12/11

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A phase 1 study of combination therapy with gemcitabine and candesartan in patients with pancreatic cancer
Acronym GECA-1 study
Scientific Title A phase 1 study of combination therapy with gemcitabine and candesartan in patients with pancreatic cancer
Scientific Title:Acronym GECA-1 study
Region
Japan

Condition
Condition Pancreatic cancer
Classification by specialty
Hepato-biliary-pancreatic medicine
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 We will investigate the safety of combination therapy with gemcitabine and candesartan and determine the maximum tolerated dose and the recommended dose.
Basic objectives2 Safety
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2 Explanatory
Developmental phase Phase I

Assessment
Primary outcomes Dose limiting toxicity, maximum tolerated dose, recommended dose
Key secondary outcomes Adverse effects, response rate, disease control rate, progression free survival, overall survival

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Combination therapy with gemcitabine and candesartan
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1) Patients with non-resectable or post-operative recurrent pancreatic cancer
2) Patients with pathologically proven or graphically confirmed pancreatic cancer
3) Patients with no prior therapy except surgery
4) Patients with Eastern Chemotherapy Oncology Group(ECOG) performance status of 0-2
5) Patients of age >= 20 years
6) Patients have an adequate organ function defined as white cell count >= 3,000/mm3, platelet count >= 100,000/mm3, hemoglobin >= 9g/dl, total bilirubin <= 3 times the upper limit of normal, AST and ALT <= 5 times the upper limit of normal, creatinine <= the upper limit of normal, and potassium <= the upper limit of normal
7) Written informed consent is required from all patients.
Key exclusion criteria 1) Patients with systolic blood pressure < 100mmHg
2) Patients with an active concomitant infection
3) Patients with digestive ulcer or gastrointestinal bleeding
4) Patients with severe heart or renal disease
5) Patients with an active pulmonary fibrosis or interstitial pneumonia
6) Patients with a previous history of a severe drug hypersensitivity
7) Patients with an active concomitant malignancy
8) Pregnant, lactating female and patients of reproductive potential who did not use effective contraception
9) Patients with hypertension
10) Patients who received ACE or ARB
11) Patients with uncontrollable massive pleural effusion or massive ascites
12) Inappropriate patients for entry on this study in the judgement of the investigator
Target sample size 24

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Hiroyuki Isayama
Organization University of Tokyo
Division name Department of Gastroenterology
Zip code
Address 7-3-1 Hongo, Bunkyo-ku, Tokyo
TEL
Email

Public contact
Name of contact person
1st name
Middle name
Last name Yousuke Nakai
Organization University of Tokyo
Division name Department of Gastroenterology
Zip code
Address
TEL
Homepage URL
Email ynakai-tky@umin.ac.jp

Sponsor
Institute University of Tokyo, Department of Gastroenterology
Institute
Department

Funding Source
Organization None
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2009 Year 07 Month 01 Day

Related information
URL releasing protocol
Publication of results Published

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Main results already published
Date of protocol fixation
2009 Year 07 Month 01 Day
Date of IRB
Anticipated trial start date
2009 Year 07 Month 01 Day
Last follow-up date
2012 Year 07 Month 01 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2009 Year 07 Month 01 Day
Last modified on
2015 Year 12 Month 11 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002632

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.